Kyntra Bio Inc. Common Stock (KYNB)

FairStock Score: 25/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Kyntra Bio as a 34-employee biotech with two pipeline programs but no visible durable moat. Its FG-3246 antibody-drug conjugate targets CD46 in metastatic castration-resistant prostate cancer, and Roxadustat has completed Phase III. Those are serious unmet needs, but clinical-stage biotech economics depend on trial results, regulatory approval, and capital, not on present earnings power. The reported numbers are erratic. In fiscal 2025, the year ended 2025-12-31, revenue was $6.4M and net income was $183.5M, versus fiscal 2024 revenue of $29.6M and a net loss of $47.6M, and fiscal 2023 revenue of $46.8M and a net loss of $284.2M. In fiscal Q2 2026, the quarter ended 2026-06-30, reported revenue was negative $1.5M and net income was $12.0M. That is not a stable compounding record. Financial health looks poor. FairStock calculates trailing free cash flow of -$38.1M and an FCF yield of -160.1% against the $23.8M market cap at the 2026-10-13 close of $5.87. Debt-to-equity is 4.37, ROCE is -22.50%, Piotroski is 3/9, and Altman Z is -23.41. FairStock's P/E is -0.77; P/B is unavailable. FairStock's score is 25/100. It labels the stock a TURNAROUND because it returned to profit after a loss within three years, but the category does not create a margin of safety. At $5.87, the price is near the 52-week low of $5.62. Without reliable positive free cash flow or a clear competitive advantage, I see speculation, not a Graham bargain.

In plain English: Kyntra Bio is a small drug company trying to develop treatments for prostate cancer and other serious illnesses. Its recent sales have been tiny and uneven, it is burning cash, and it carries a lot of debt, so the business looks weak. At $5.87, the stock sits near the low end of its yearly range, but based on the numbers shown it does not look clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer